论文部分内容阅读
目的探讨糖尿病肾病(DN)患者血清血小板内皮细胞黏附分子1(PECAM-1)的表达及其临床意义。方法 ELISA法检测20例DN患者(DN组)血清PECAM-1,高效液相法检测糖化血红蛋白(HbA1c),生化法检测血糖(Glu),全血细胞分析仪测定血小板计数(Plt);其结果与19例2型糖尿病患者(T2DM组)及16例正常人(C组)比较。结果 DN组PECAM-1、Glu、HbA1c水平高于C组(P<0.01)。T2DM组PECAM-1与Glu、HbA1c水平呈正相关(P<0.01),Glu与HbA1c水平呈正相关(P<0.05)。结论血清PECAM-1高表达是促进T2DM患者血管内皮细胞内皮损伤和肾功能损害的重要因素;血清PECAM-1水平可作为该类疾病治疗效果评价及并发症发生的预测指标。
Objective To investigate the expression of serum platelet adhesion molecule-1 (PECAM-1) in patients with diabetic nephropathy (DN) and its clinical significance. Methods Serum levels of PECAM-1 in 20 DN patients (DN group) were detected by ELISA. HbA1c was detected by high performance liquid chromatography, Glu was measured by biochemical method and Plt was measured by whole blood cell analyzer. 19 patients with type 2 diabetes (T2DM group) and 16 normal subjects (group C). Results The levels of PECAM-1, Glu and HbA1c in DN group were higher than those in C group (P <0.01). There was a positive correlation between PECAM-1 and Glu and HbA1c levels in T2DM patients (P <0.01), Glu and HbA1c levels were positively correlated (P <0.05). Conclusion High expression of serum PECAM-1 is an important factor to promote endothelial dysfunction and endothelial dysfunction in T2DM patients. Serum PECAM-1 level can be used as a predictor of the therapeutic effect and complications of T2DM.